Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Spyre Therapeutics
Biotech
Spyre’s rheumatoid arthritis plan toppled by subpar TL1A data
Phase 2 data on Spyre’s anti-TL1A antibody fell short of expectations, prompting the biotech to deprioritize monotherapy work in the indication.
Nick Paul Taylor
Aug 26, 2026 5:40am
Bionyra emerges with $165M and three licensed I&I assets
Jun 22, 2026 7:00am
Spyre bolsters ulcerative colitis ambitions with ph. 2 win
Jun 15, 2026 3:19pm
Spyre touts ph. 2 UC win as proof it could surpass Entyvio
Apr 13, 2026 9:55am
BMS snags top neuro researcher from Eisai—Chutes & Ladders
Jan 23, 2026 8:30am
Prothena promotes one exec while another leaves—Chutes & Ladders
Oct 4, 2024 8:00am
